32-OR: The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial

医学 狼牙棒 内科学 安慰剂 临床终点 心肌梗塞 心力衰竭 冲程(发动机) 不稳定型心绞痛 2型糖尿病 比例危险模型 心脏病学 糖尿病 随机对照试验 内分泌学 传统PCI 替代医学 病理 工程类 机械工程
作者
John J.V. McMurray,Mason W. Freeman,Joseph M. Massaro,Scott D. Solomon,Paul Lock,Matthew C. Riddle,Eldrin F. Lewis,Yuan‐Di C. Halvorsen
出处
期刊:Diabetes [American Diabetes Association]
卷期号:69 (Supplement_1) 被引量:11
标识
DOI:10.2337/db20-32-or
摘要

Bexagliflozin (bexa) is a potent and selective inhibitor of SGLT2. To demonstrate its effects in patients (pts) at increased risk of cardiovascular (CV) events, pts with type 2 diabetes (T2D) ≥40 years old with HbA1c 7.5-11 % and eGFR ≥45 were enrolled in 1 of 3 groups: 1) established atherosclerotic CVD 2) heart failure (HF) or 3) ≥55 years with ≥2 CV risk factors. The primary endpoint was change in HbA1c at wk 24. Secondary endpoints included change in SBP at 24 wks in pts with SBP ≥140 mmHg, weight loss at 48 wks in pts with BMI ≥25 kg/m2, and time to hospitalization for HF or CV death. MACE+ (CV death, myocardial infarction, stroke, or unstable angina) was tested in a non-inferiority analysis to demonstrate upper 95% CI <1.8. Pts were randomized 2:1 to bexa 20 mg or placebo qd. Follow-up continued until all pts completed ≥52 wks and when ≥134 subjects had a MACE+ event. CV endpoints and deaths were adjudicated and analyzed using Cox proportional hazards regression. Placebo-corrected changes from baseline in HbA1c, weight and SBP were analyzed using a mixed model repeated measures approach to account for missing data. 1700 pts were enrolled (62.6% Group1, 14.5% Group 2, 22.9% in Group 3) and followed for a median of 30 months. At baseline mean (SD) HbA1c was 8.32 (0.91)%; BMI 32.6 (6.0) kg/m2 (92%≥25); SBP 134 (16) mmHg (39% ≥140); eGFR 77.9 (19.5) (19% <60). The primary endpoint showed a placebo-corrected reduction in HbA1c of 0.48% (95% CI -0.56, -0.39), p<0.0001; SBP fell 3.0 mmHg (- 5.5, -0.4), p=0.02; and weight declined 2.7kg (-3.1, -2.2), p<0.0001. CV death or HF hosp. occurred in 48 (4.2%) pts on bexa and 31 (5.5%) on placebo: HR 0.74 (0.47, 1.17). MACE+ occurred in 90/1133 (7.9%) pts on bexa and 57/567 (10.1%) on placebo: HR 0.79 (95%CI 0.56, 1.09). In high-risk T2D pts, bexagliflozin was well tolerated and improved HbA1c, SBP, and weight. Non-inferiority was demonstrated for MACE+, with point-estimates for MACE+ and CV death or HF hosp similar to other SGLT2 inhibitors. Disclosure J.J.V. McMurray: Other Relationship; Self; AbbVie Inc., Alnylam Pharmaceuticals, Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Bristol-Myers Squibb, Cardurion, GlaxoSmithKline plc., Novartis Pharmaceuticals Corporation, Theracos, Inc. M.W. Freeman: Research Support; Self; Theracos, Inc. J. Massaro: Consultant; Self; Theracos, Inc. S. Solomon: Consultant; Self; AstraZeneca, Theracos, Inc. Research Support; Self; AstraZeneca, Theracos, Inc. P. Lock: None. M.C. Riddle: Consultant; Self; ADOCIA, Dance Biopharm Holdings, Inc., GlaxoSmithKline plc., Sanofi US, Theracos, Inc. Research Support; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk Inc. E. Lewis: Consultant; Self; Novartis Pharmaceuticals Corporation. Research Support; Self; Amgen, Novartis Pharmaceuticals Corporation, Theracos, Inc. Y.C. Halvorsen: Research Support; Self; Theracos, Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
英俊的铭应助downloadpapers采纳,获得10
3秒前
Owen应助钟博士采纳,获得10
4秒前
4秒前
宇哈哈完成签到,获得积分10
4秒前
nianxunxi完成签到,获得积分10
4秒前
爆米花应助nehsiac采纳,获得10
5秒前
ZZZ完成签到,获得积分10
6秒前
宇哈哈发布了新的文献求助10
6秒前
活泼的诗桃完成签到,获得积分10
6秒前
在下吴某完成签到 ,获得积分10
8秒前
讨厌下雨发布了新的文献求助10
8秒前
雅姗灬姗完成签到,获得积分10
9秒前
大胆胡萝卜完成签到,获得积分10
11秒前
天启完成签到,获得积分10
12秒前
爆米花应助宇哈哈采纳,获得10
13秒前
14秒前
15秒前
15秒前
15秒前
626发布了新的文献求助30
15秒前
15秒前
清水完成签到,获得积分10
18秒前
19秒前
20秒前
猛犸象冲冲冲完成签到,获得积分10
20秒前
优雅语兰发布了新的文献求助10
20秒前
20秒前
独特尔丝发布了新的文献求助10
20秒前
20秒前
20秒前
醉翁完成签到,获得积分10
21秒前
浅尝离白应助默默纲采纳,获得30
21秒前
搬工的砖人完成签到,获得积分10
21秒前
Pluto发布了新的文献求助20
22秒前
共享精神应助木子李采纳,获得10
22秒前
22秒前
23秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140698
求助须知:如何正确求助?哪些是违规求助? 2791571
关于积分的说明 7799545
捐赠科研通 2447907
什么是DOI,文献DOI怎么找? 1302182
科研通“疑难数据库(出版商)”最低求助积分说明 626459
版权声明 601194